Integrated Diagnostics Finds $6.1M For Lung Cancer Diagnostics

Seattle-based Indi (Integrated Diagnostics) said on Friday that it has raised $6.1M in a financing round, for its development of a molecular diagnostic blood test which helps diagnose lung cancer. The Series C funding came from Baird Capital and InterWest Partners. Indi, which is led by CEO Albert A. Luderer, Ph.D., is developing a noninvasive blood test which helps physicians identify "diagnostically challenging" patients, who have benign lung nodules. More information »